| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Regulus Therapeutics Inc (F: 7RG1)
7RG1 Technical Analysis
5
| As on 28th Jun 2022 7RG1 STOCK Price closed @ 0.15 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.80 & Strong Sell for SHORT-TERM with Stoploss of 1.23 we also expect STOCK to react on Following IMPORTANT LEVELS. |
7RG1STOCK Price
| Open | 0.15 | Change | Price | % |
| High | 0.15 | 1 Day | -0.07 | -31.82 |
| Low | 0.15 | 1 Week | -0.07 | -31.82 |
| Close | 0.15 | 1 Month | -0.02 | -11.76 |
| Volume | 9090 | 1 Year | -0.78 | -83.87 |
| 52 Week High 1.61 | 52 Week Low 0.12 | ||||
F Germany Most Active Stocks
| IMU | 0.10 | -99.65% |
| IMU | 0.10 | -99.65% |
| IMU | 0.10 | -99.65% |
| IMU | 0.10 | -99.65% |
| IMU | 0.10 | -99.65% |
| ENB | 47.60 | -0.92% |
| TEF | 3.84 | -0.52% |
| TEF | 3.84 | -0.52% |
| WHL | 5150.00 | -0.44% |
| WDI | 0.05 | -37.50% |
F Germany Top Gainers Stocks
F Germany Top Losers Stocks
| 7RG1 Daily Charts |
7RG1 Intraday Charts |
Whats New @ Bazaartrend |
7RG1 Free Analysis |
|
|
7RG1 Important Levels Intraday
| RESISTANCE | 0.15 |
| RESISTANCE | 0.15 |
| RESISTANCE | 0.15 |
| RESISTANCE | 0.15 |
| RESISTANCE | 0.15 |
| RESISTANCE | 0.15 |
| RESISTANCE | 0.15 |
| RESISTANCE | 0.15 |
7RG1 Forecast November 2024
| 4th UP Forecast | 1.44 |
| 3rd UP Forecast | 1.03 |
| 2nd UP Forecast | 0.77 |
| 1st UP Forecast | 0.52 |
| 1st DOWN Forecast | -0.22 |
| 2nd DOWN Forecast | -0.47 |
| 3rd DOWN Forecast | -0.73 |
| 4th DOWN Forecast | -1.14 |
7RG1 Weekly Forecast
| 4th UP Forecast | 1.11 |
| 3rd UP Forecast | 0.80 |
| 2nd UP Forecast | 0.61 |
| 1st UP Forecast | 0.42 |
| 1st DOWN Forecast | -0.12 |
| 2nd DOWN Forecast | -0.31 |
| 3rd DOWN Forecast | -0.50 |
| 4th DOWN Forecast | -0.81 |
7RG1 Forecast2024
| 4th UP Forecast | 3.33 |
| 3rd UP Forecast | 2.31 |
| 2nd UP Forecast | 1.68 |
| 1st UP Forecast | 1.05 |
| 1st DOWN Forecast | -0.75 |
| 2nd DOWN Forecast | -1.38 |
| 3rd DOWN Forecast | -2.01 |
| 4th DOWN Forecast | -3.03 |
Regulus Therapeutics Inc ( F Germany Symbol : 7RG1 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
7RG1 Business Profile
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase 1 development for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 glioblastoma multiforme program; and Hepatitis B virus, non-alcoholic steatohepatitis, and cell therapies programs. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. Address: 4224 Campus Point Court, San Diego, CA, United States, 92121
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service